Charles Schwab’s Atrium Therapeutics RNA Stock Holding History

Charles Schwab’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Buy	130,217 +13,619	+12%	+$178K	﹤0.01%	2831
2026 Q1	$1.56M	Buy	+116,598	New	+$1.64M	﹤0.01%	2772

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Charles Schwab's RNA Position: Q2 2026 in Review

Charles Schwab increased its Atrium Therapeutics (RNA) stake by 12% in Q2 2026, buying an estimated $178K and bringing the position to 130,217 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2831.

Charles Schwab first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Charles Schwab held 130,217 shares of Atrium Therapeutics worth $1.75M as of Q2 2026.
Charles Schwab bought 13,619 Atrium Therapeutics shares in Q2 2026, an estimated $178K.
Atrium Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2831 holding.
Charles Schwab first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.